SILENCE THERAP. SP.ADR/1 Cash Flow Reinvestment Rate

Latest as of December 2021: 1.67x

SILENCE THERAP. SP.ADR/1 cash flow reinvestment rate. SILENCE THERAP. SP.ADR/1 (XRP2) has a Cash Flow Reinvestment Rate of 1.67x as of December 2021, reinvesting €15.30 Million (capex €1.80 Million plus investments €13.50 Million) from operating cash flow of €9.19 Million. Explore XRP2 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

1.67x

(Capex + Investments) / Operating CF

Total Reinvested

€15.30 Million

Capex + Investments

Operating Cash Flow

€9.19 Million

EUR

Capital Expenditures

€1.80 Million

EUR

Cash Flow Reinvestment Rate of SILENCE THERAP. SP.ADR/1 (2021–2021)

Cash flow reinvestment rate of SILENCE THERAP. SP.ADR/1 from 2021 to 2021. Historical reinvestment intensity for SILENCE THERAP. SP.ADR/1 across 1 annual periods. Explore SILENCE THERAP. SP.ADR/1 capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

SILENCE THERAP. SP.ADR/1 Cash Flow Reinvestment Rate by Year (2021–2021)

SILENCE THERAP. SP.ADR/1 cash flow reinvestment rate by year from 2021 to 2021. Year-by-year capital reinvestment analysis for SILENCE THERAP. SP.ADR/1. For the full cash flow conversion analysis, see SILENCE THERAP. SP.ADR/1 cash flow conversion.

Year	Reinvestment Rate	Total Reinvested (EUR)	Operating CF	Capex	YoY Change
2021	1.67x	€15.30 Million	€9.19 Million	€1.80 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow